Puran Bora
Concepts (272)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Choroidal Neovascularization | 18 | 2023 | 65 | 6.900 |
Why?
| Adiponectin | 13 | 2023 | 76 | 3.250 |
Why?
| Wet Macular Degeneration | 4 | 2023 | 15 | 3.120 |
Why?
| Disease Models, Animal | 22 | 2022 | 1639 | 1.890 |
Why?
| Macular Degeneration | 9 | 2016 | 49 | 1.790 |
Why?
| Geographic Atrophy | 3 | 2023 | 9 | 1.570 |
Why?
| Choroid | 5 | 2012 | 26 | 1.310 |
Why?
| Angiogenesis Inhibitors | 3 | 2023 | 203 | 1.260 |
Why?
| Complement System Proteins | 7 | 2014 | 55 | 1.180 |
Why?
| Lasers | 8 | 2011 | 141 | 1.150 |
Why?
| Vascular Endothelial Growth Factor A | 10 | 2023 | 230 | 1.110 |
Why?
| Autoimmune Diseases | 10 | 2019 | 114 | 1.000 |
Why?
| Uveitis, Anterior | 9 | 2019 | 28 | 0.970 |
Why?
| Animals | 47 | 2023 | 14385 | 0.970 |
Why?
| Complement Membrane Attack Complex | 6 | 2011 | 21 | 0.910 |
Why?
| Diabetic Retinopathy | 1 | 2023 | 41 | 0.890 |
Why?
| Polyethylene Glycols | 2 | 2014 | 106 | 0.850 |
Why?
| Mice | 22 | 2023 | 6413 | 0.820 |
Why?
| Trityl Compounds | 1 | 2020 | 3 | 0.770 |
Why?
| Butyric Acid | 1 | 2020 | 10 | 0.770 |
Why?
| Acetamides | 1 | 2020 | 25 | 0.750 |
Why?
| Retinal Pigment Epithelium | 3 | 2016 | 24 | 0.740 |
Why?
| Receptors, Adiponectin | 6 | 2023 | 14 | 0.740 |
Why?
| Peptide Fragments | 2 | 2012 | 242 | 0.710 |
Why?
| Ethanol | 3 | 2008 | 322 | 0.700 |
Why?
| Complement Factor H | 2 | 2010 | 10 | 0.670 |
Why?
| Nicotine | 2 | 2012 | 207 | 0.670 |
Why?
| Mice, Inbred C57BL | 11 | 2020 | 1999 | 0.650 |
Why?
| Thalidomide | 1 | 2020 | 397 | 0.640 |
Why?
| Neovascularization, Pathologic | 2 | 2010 | 168 | 0.550 |
Why?
| Autoantigens | 5 | 2009 | 64 | 0.510 |
Why?
| Photoreceptor Cells, Vertebrate | 1 | 2014 | 4 | 0.510 |
Why?
| Complement C3 | 4 | 2014 | 31 | 0.500 |
Why?
| Testis | 3 | 2019 | 65 | 0.500 |
Why?
| Complement Activation | 8 | 2010 | 43 | 0.490 |
Why?
| Recombinant Proteins | 4 | 2019 | 569 | 0.460 |
Why?
| Proliferating Cell Nuclear Antigen | 4 | 2022 | 82 | 0.450 |
Why?
| Models, Biological | 3 | 2018 | 823 | 0.440 |
Why?
| Vascular Endothelial Growth Factors | 1 | 2012 | 16 | 0.440 |
Why?
| Chemokine CCL2 | 2 | 2016 | 78 | 0.430 |
Why?
| Transforming Growth Factor beta2 | 5 | 2019 | 17 | 0.420 |
Why?
| Gene Expression Regulation | 4 | 2014 | 1062 | 0.420 |
Why?
| Cell Proliferation | 8 | 2020 | 1096 | 0.410 |
Why?
| Eye Diseases | 3 | 2008 | 35 | 0.400 |
Why?
| Male | 29 | 2020 | 27312 | 0.390 |
Why?
| Complement Factor B | 2 | 2011 | 9 | 0.390 |
Why?
| Complement Pathway, Alternative | 2 | 2011 | 11 | 0.390 |
Why?
| Pigment Epithelium of Eye | 1 | 2010 | 15 | 0.380 |
Why?
| Drug Carriers | 1 | 2011 | 81 | 0.380 |
Why?
| Eye | 3 | 2006 | 36 | 0.380 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 240 | 0.370 |
Why?
| Polycystic Ovary Syndrome | 3 | 2018 | 11 | 0.360 |
Why?
| Alcohol Drinking | 2 | 2008 | 259 | 0.340 |
Why?
| Rats | 17 | 2019 | 3415 | 0.340 |
Why?
| Rats, Inbred Lew | 13 | 2019 | 67 | 0.330 |
Why?
| Antioxidants | 3 | 2019 | 297 | 0.320 |
Why?
| Collagen Type I | 2 | 2009 | 97 | 0.320 |
Why?
| Reproduction | 2 | 2018 | 56 | 0.320 |
Why?
| Acyltransferases | 2 | 2006 | 27 | 0.310 |
Why?
| Esters | 1 | 2006 | 25 | 0.280 |
Why?
| Retina | 2 | 2023 | 64 | 0.280 |
Why?
| Receptor, Insulin | 4 | 2019 | 44 | 0.270 |
Why?
| Uveitis | 4 | 2009 | 28 | 0.270 |
Why?
| Peptides | 2 | 2022 | 276 | 0.260 |
Why?
| Fatty Acids | 1 | 2006 | 174 | 0.260 |
Why?
| Immune Tolerance | 5 | 2009 | 104 | 0.260 |
Why?
| Apoptosis | 6 | 2018 | 1300 | 0.260 |
Why?
| Immunohistochemistry | 5 | 2014 | 1089 | 0.260 |
Why?
| Mice, Knockout | 5 | 2016 | 926 | 0.250 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2014 | 673 | 0.240 |
Why?
| Carboxylic Ester Hydrolases | 1 | 2003 | 6 | 0.240 |
Why?
| Mutagenesis, Site-Directed | 1 | 2003 | 117 | 0.240 |
Why?
| Intercellular Signaling Peptides and Proteins | 2 | 2018 | 122 | 0.230 |
Why?
| Fluorescein-5-isothiocyanate | 1 | 2022 | 11 | 0.220 |
Why?
| Ophthalmic Solutions | 1 | 2022 | 27 | 0.220 |
Why?
| Humans | 14 | 2023 | 54246 | 0.210 |
Why?
| Visual Acuity | 1 | 2023 | 143 | 0.210 |
Why?
| Blotting, Western | 7 | 2016 | 683 | 0.210 |
Why?
| Diabetes Mellitus | 2 | 2023 | 307 | 0.200 |
Why?
| Time Factors | 3 | 2014 | 3212 | 0.190 |
Why?
| Rats, Inbred BN | 2 | 2012 | 21 | 0.190 |
Why?
| Down-Regulation | 3 | 2007 | 388 | 0.190 |
Why?
| Myocardium | 1 | 2003 | 441 | 0.190 |
Why?
| Immunotherapy | 1 | 2003 | 263 | 0.190 |
Why?
| Androgens | 2 | 2018 | 68 | 0.190 |
Why?
| Amino Acid Sequence | 3 | 2009 | 767 | 0.180 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2020 | 95 | 0.180 |
Why?
| Cell Line | 2 | 2020 | 1153 | 0.180 |
Why?
| RNA, Small Interfering | 3 | 2010 | 252 | 0.180 |
Why?
| Chemokines | 2 | 2018 | 96 | 0.170 |
Why?
| Complement C4 | 2 | 2011 | 8 | 0.170 |
Why?
| Injections, Intraocular | 2 | 2019 | 7 | 0.170 |
Why?
| Antigens, Surface | 3 | 2010 | 55 | 0.170 |
Why?
| T-Lymphocytes, Regulatory | 2 | 2009 | 85 | 0.170 |
Why?
| Endothelial Cells | 2 | 2012 | 294 | 0.160 |
Why?
| Diabetes Mellitus, Experimental | 1 | 2019 | 140 | 0.160 |
Why?
| Enzyme-Linked Immunosorbent Assay | 5 | 2016 | 314 | 0.160 |
Why?
| CD4-Positive T-Lymphocytes | 2 | 2011 | 180 | 0.160 |
Why?
| Ovary | 1 | 2018 | 105 | 0.160 |
Why?
| Metabolic Diseases | 1 | 2018 | 43 | 0.160 |
Why?
| Adoptive Transfer | 5 | 2011 | 38 | 0.150 |
Why?
| In Situ Nick-End Labeling | 2 | 2014 | 64 | 0.140 |
Why?
| RNA, Messenger | 3 | 2010 | 1202 | 0.140 |
Why?
| Transforming Growth Factor beta | 3 | 2006 | 158 | 0.140 |
Why?
| Retinal Degeneration | 1 | 2016 | 16 | 0.140 |
Why?
| Protein Processing, Post-Translational | 2 | 2009 | 183 | 0.140 |
Why?
| Cells, Cultured | 3 | 2012 | 1737 | 0.130 |
Why?
| Cyclin E | 2 | 2006 | 6 | 0.130 |
Why?
| Antigens, Neoplasm | 2 | 2008 | 170 | 0.130 |
Why?
| Complement C1 Inhibitor Protein | 1 | 2014 | 5 | 0.130 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 142 | 0.130 |
Why?
| Aspirin | 1 | 2016 | 127 | 0.130 |
Why?
| Body Mass Index | 1 | 2018 | 712 | 0.130 |
Why?
| Aminopeptidases | 1 | 2014 | 18 | 0.130 |
Why?
| Testosterone | 3 | 2019 | 119 | 0.120 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2014 | 93 | 0.120 |
Why?
| Serine Endopeptidases | 1 | 2014 | 57 | 0.120 |
Why?
| Wound Healing | 2 | 2016 | 228 | 0.120 |
Why?
| Microscopy, Confocal | 2 | 2005 | 110 | 0.120 |
Why?
| Injections, Intravenous | 3 | 2009 | 148 | 0.110 |
Why?
| Interleukin-2 Receptor alpha Subunit | 2 | 2009 | 12 | 0.110 |
Why?
| Aging | 1 | 2018 | 784 | 0.110 |
Why?
| Bungarotoxins | 1 | 2012 | 7 | 0.110 |
Why?
| Intravitreal Injections | 1 | 2012 | 40 | 0.110 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2012 | 37 | 0.110 |
Why?
| Autophagy | 1 | 2014 | 202 | 0.110 |
Why?
| Receptors, Cell Surface | 2 | 2010 | 130 | 0.110 |
Why?
| Molecular Sequence Data | 2 | 2004 | 980 | 0.110 |
Why?
| Receptors, Nicotinic | 1 | 2012 | 80 | 0.100 |
Why?
| Honey | 1 | 2011 | 8 | 0.100 |
Why?
| Keratitis | 1 | 2011 | 17 | 0.100 |
Why?
| Complement C9 | 1 | 2011 | 3 | 0.100 |
Why?
| Pseudomonas Infections | 1 | 2011 | 54 | 0.100 |
Why?
| Eye Injuries | 1 | 2011 | 29 | 0.100 |
Why?
| Eye Infections, Bacterial | 1 | 2011 | 35 | 0.100 |
Why?
| Antibodies, Neutralizing | 1 | 2011 | 75 | 0.100 |
Why?
| Vision, Ocular | 1 | 2010 | 13 | 0.100 |
Why?
| Analysis of Variance | 1 | 2012 | 635 | 0.100 |
Why?
| Dose-Response Relationship, Drug | 1 | 2014 | 1476 | 0.090 |
Why?
| Immunoenzyme Techniques | 1 | 2010 | 165 | 0.090 |
Why?
| Immunoglobulin G | 2 | 2011 | 226 | 0.090 |
Why?
| Epitopes | 1 | 2009 | 89 | 0.090 |
Why?
| Gene Expression | 1 | 2012 | 664 | 0.090 |
Why?
| Cell Membrane | 1 | 2010 | 278 | 0.090 |
Why?
| Cyclin-Dependent Kinase 2 | 2 | 2006 | 28 | 0.080 |
Why?
| Protein Structure, Tertiary | 1 | 2009 | 289 | 0.080 |
Why?
| Aged | 1 | 2022 | 10041 | 0.080 |
Why?
| Models, Animal | 1 | 2009 | 255 | 0.080 |
Why?
| Cattle | 4 | 2009 | 224 | 0.080 |
Why?
| Lipid Peroxidation | 2 | 2018 | 132 | 0.080 |
Why?
| Diet | 2 | 2016 | 597 | 0.080 |
Why?
| Growth Substances | 1 | 2007 | 32 | 0.080 |
Why?
| Complement C3b | 2 | 2006 | 8 | 0.070 |
Why?
| Complement C5 | 1 | 2006 | 3 | 0.070 |
Why?
| Complement C1q | 1 | 2006 | 11 | 0.070 |
Why?
| Complement Inactivator Proteins | 1 | 2006 | 5 | 0.070 |
Why?
| Glucose | 2 | 2019 | 366 | 0.070 |
Why?
| Cell Survival | 2 | 2018 | 657 | 0.070 |
Why?
| Recombinant Fusion Proteins | 1 | 2007 | 206 | 0.070 |
Why?
| Immunity, Innate | 1 | 2007 | 114 | 0.070 |
Why?
| Inflammation | 1 | 2010 | 674 | 0.070 |
Why?
| Models, Molecular | 1 | 2007 | 423 | 0.070 |
Why?
| Lipoxygenase Inhibitors | 1 | 2005 | 6 | 0.070 |
Why?
| Risk Factors | 1 | 2014 | 3930 | 0.070 |
Why?
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 26 | 0.070 |
Why?
| Cyclooxygenase Inhibitors | 1 | 2005 | 44 | 0.070 |
Why?
| Nitric Oxide Synthase | 1 | 2005 | 102 | 0.060 |
Why?
| Immunologic Factors | 1 | 2006 | 130 | 0.060 |
Why?
| Immune Sera | 1 | 2004 | 24 | 0.060 |
Why?
| Fibroblast Growth Factors | 1 | 2005 | 59 | 0.060 |
Why?
| Up-Regulation | 1 | 2006 | 508 | 0.060 |
Why?
| Sequence Homology | 1 | 2003 | 21 | 0.060 |
Why?
| Caspase 3 | 2 | 2018 | 135 | 0.060 |
Why?
| COS Cells | 1 | 2003 | 78 | 0.060 |
Why?
| Organ Specificity | 1 | 2004 | 126 | 0.060 |
Why?
| Linolenic Acids | 1 | 2003 | 2 | 0.060 |
Why?
| CDC2-CDC28 Kinases | 1 | 2003 | 15 | 0.060 |
Why?
| Kupffer Cells | 1 | 2003 | 18 | 0.060 |
Why?
| Signal Transduction | 3 | 2018 | 1753 | 0.060 |
Why?
| Thromboplastin | 1 | 2003 | 8 | 0.060 |
Why?
| Avian Proteins | 1 | 2003 | 6 | 0.060 |
Why?
| Gene Library | 1 | 2003 | 50 | 0.060 |
Why?
| Enzyme Activation | 1 | 2003 | 329 | 0.060 |
Why?
| Antigen-Presenting Cells | 1 | 2003 | 25 | 0.060 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2018 | 158 | 0.060 |
Why?
| Adenoviridae | 1 | 2003 | 58 | 0.060 |
Why?
| DNA, Complementary | 1 | 2003 | 145 | 0.060 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2003 | 169 | 0.060 |
Why?
| Structure-Activity Relationship | 1 | 2003 | 423 | 0.050 |
Why?
| Tumor Suppressor Proteins | 1 | 2003 | 141 | 0.050 |
Why?
| Blood Proteins | 1 | 2003 | 100 | 0.050 |
Why?
| Genetic Vectors | 1 | 2003 | 139 | 0.050 |
Why?
| Cell Cycle Proteins | 1 | 2003 | 199 | 0.050 |
Why?
| Cytokines | 3 | 2011 | 676 | 0.050 |
Why?
| Swine | 1 | 2003 | 431 | 0.050 |
Why?
| Antigens, CD | 1 | 2003 | 242 | 0.050 |
Why?
| Protein Binding | 1 | 2003 | 736 | 0.050 |
Why?
| Glucose Transport Proteins, Facilitative | 1 | 2019 | 10 | 0.050 |
Why?
| Lactic Acid | 1 | 2019 | 90 | 0.040 |
Why?
| Specific Pathogen-Free Organisms | 2 | 2009 | 15 | 0.040 |
Why?
| Melanins | 2 | 2011 | 30 | 0.040 |
Why?
| Adenylate Kinase | 1 | 2018 | 10 | 0.040 |
Why?
| Adipokines | 1 | 2018 | 12 | 0.040 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2018 | 101 | 0.040 |
Why?
| Receptors, LH | 1 | 2018 | 4 | 0.040 |
Why?
| L-Lactate Dehydrogenase | 1 | 2018 | 79 | 0.040 |
Why?
| Dehydroepiandrosterone | 1 | 2018 | 16 | 0.040 |
Why?
| Organ Size | 1 | 2018 | 237 | 0.040 |
Why?
| Animals, Newborn | 1 | 2018 | 396 | 0.040 |
Why?
| Phosphoproteins | 1 | 2018 | 116 | 0.040 |
Why?
| Phosphorylation | 1 | 2018 | 614 | 0.040 |
Why?
| Mutation | 1 | 2003 | 1501 | 0.040 |
Why?
| Mice, Inbred Strains | 1 | 2017 | 198 | 0.040 |
Why?
| Estradiol | 1 | 2018 | 219 | 0.040 |
Why?
| Lymph Nodes | 2 | 2009 | 284 | 0.040 |
Why?
| Triglycerides | 1 | 2018 | 195 | 0.040 |
Why?
| Liver | 1 | 2003 | 1225 | 0.040 |
Why?
| T-Lymphocytes | 1 | 2019 | 373 | 0.040 |
Why?
| Female | 4 | 2018 | 28418 | 0.040 |
Why?
| Body Weight | 1 | 2018 | 578 | 0.030 |
Why?
| Nitric Oxide | 1 | 2018 | 298 | 0.030 |
Why?
| Blood Glucose | 1 | 2018 | 488 | 0.030 |
Why?
| Oxidative Stress | 1 | 2019 | 958 | 0.030 |
Why?
| Follow-Up Studies | 2 | 2011 | 2387 | 0.030 |
Why?
| Endotoxins | 1 | 2011 | 37 | 0.030 |
Why?
| Administration, Topical | 1 | 2011 | 71 | 0.030 |
Why?
| Cornea | 1 | 2011 | 62 | 0.020 |
Why?
| Pseudomonas aeruginosa | 1 | 2011 | 86 | 0.020 |
Why?
| Fluorescent Antibody Technique | 1 | 2010 | 141 | 0.020 |
Why?
| RNA | 1 | 2011 | 202 | 0.020 |
Why?
| Autoantibodies | 1 | 2011 | 132 | 0.020 |
Why?
| Lymphocyte Depletion | 1 | 2009 | 12 | 0.020 |
Why?
| Immunization | 1 | 2009 | 95 | 0.020 |
Why?
| Obesity | 1 | 2018 | 1197 | 0.020 |
Why?
| Lymphocyte Count | 1 | 2008 | 23 | 0.020 |
Why?
| Forkhead Transcription Factors | 1 | 2009 | 118 | 0.020 |
Why?
| Interleukin-2 | 1 | 2008 | 75 | 0.020 |
Why?
| Coculture Techniques | 1 | 2008 | 160 | 0.020 |
Why?
| Caspase 8 | 1 | 2007 | 16 | 0.020 |
Why?
| Caspase 9 | 1 | 2007 | 20 | 0.020 |
Why?
| Cytochromes c | 1 | 2007 | 41 | 0.020 |
Why?
| bcl-2-Associated X Protein | 1 | 2007 | 73 | 0.020 |
Why?
| Treatment Outcome | 2 | 2011 | 5604 | 0.020 |
Why?
| Anterior Chamber | 1 | 2007 | 10 | 0.020 |
Why?
| Complement C3-C5 Convertases | 1 | 2006 | 3 | 0.020 |
Why?
| Oligodeoxyribonucleotides, Antisense | 1 | 2006 | 4 | 0.020 |
Why?
| Receptors, Complement | 1 | 2006 | 4 | 0.020 |
Why?
| Antibodies, Blocking | 1 | 2006 | 8 | 0.020 |
Why?
| Macrophage-1 Antigen | 1 | 2006 | 8 | 0.020 |
Why?
| Fluorescent Antibody Technique, Indirect | 1 | 2006 | 26 | 0.020 |
Why?
| Cell Adhesion Molecules | 1 | 2006 | 87 | 0.020 |
Why?
| Arachidonate 5-Lipoxygenase | 1 | 2005 | 4 | 0.020 |
Why?
| Cyclooxygenase 2 Inhibitors | 1 | 2005 | 20 | 0.020 |
Why?
| Cyclooxygenase 2 | 1 | 2005 | 49 | 0.020 |
Why?
| Injections, Subcutaneous | 1 | 2005 | 58 | 0.020 |
Why?
| Nitric Oxide Synthase Type II | 1 | 2005 | 83 | 0.020 |
Why?
| Guanidines | 1 | 2005 | 36 | 0.020 |
Why?
| Flow Cytometry | 1 | 2007 | 546 | 0.020 |
Why?
| Macrophages | 1 | 2007 | 405 | 0.020 |
Why?
| Pyrazoles | 1 | 2005 | 110 | 0.020 |
Why?
| Sulfonamides | 1 | 2005 | 146 | 0.010 |
Why?
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2003 | 21 | 0.010 |
Why?
| Cyclin-Dependent Kinases | 1 | 2003 | 35 | 0.010 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2003 | 78 | 0.010 |
Why?
| Transcription Factor AP-1 | 1 | 2003 | 64 | 0.010 |
Why?
| Hypersensitivity, Delayed | 1 | 2003 | 21 | 0.010 |
Why?
| Interleukin-12 | 1 | 2003 | 37 | 0.010 |
Why?
| Disease Progression | 1 | 2006 | 913 | 0.010 |
Why?
| Transfection | 1 | 2003 | 399 | 0.010 |
Why?
| Interleukin-10 | 1 | 2003 | 107 | 0.010 |
Why?
| Membrane Glycoproteins | 1 | 2003 | 269 | 0.010 |
Why?
| Antibodies, Monoclonal | 1 | 2006 | 562 | 0.010 |
Why?
|
|
Bora's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|